Global Retirement Partners’s Coherus Oncology CHRS Stock Holding History

Global Retirement Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-32	Closed	–	–	2697
2022 Q1	$0	Buy	+32	New	+$407	﹤0.01%	2646

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Global Retirement Partners's CHRS Position: Q2 2022 in Review

Global Retirement Partners sold out of Coherus Oncology (CHRS) in Q2 2022, closing a stake of 32 shares.

Global Retirement Partners first reported a position in CHRS in Q1 2022 and held it in 1 quarter. The position peaked at $0 in Q1 2022. 176 funds tracked by Wall St. Rank hold CHRS as of Q2 2022.

Global Retirement Partners reported no remaining Coherus Oncology position as of Q2 2022 after selling out during the quarter.
Global Retirement Partners sold 32 Coherus Oncology shares in Q2 2022.
Global Retirement Partners first reported a position in Coherus Oncology in Q1 2022 and held it in 1 quarter.
Global Retirement Partners's Coherus Oncology position peaked at $0 in Q1 2022.
176 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2022.

Based on Global Retirement Partners's 13F filing for Q2 2022, filed 15 Jul 2022.